Juanpere et al. [19] found that mutations in FGFR3 and PIK3CA, singly or combined with RAS and Akt1, were associated with Akt but not with MAPK pathway activation in urothelial bladder cancer. This evidence concerns the gene AKT1 and bladder transitional cell carcinoma.